



The Specialist
in Cancer Care

November 10, 2016

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub : Disclosure of the Outcome of the Board Meeting under Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref : HealthCare Global Enterprises Limited ("the Company") (NSE Scrip Code: HCG/ BSE Scrip Code: 539787)

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at their meeting held this day, November 10, 2016, *inter alia*, has approved the Financial Results (Limited Review), both Standalone and Consolidated for the quarter and half year ended September 30, 2016.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:


1. Financial Results (Limited Review), both Standalone and Consolidated for the quarter and half year ended September 30, 2016.
2. Limited Review Report on the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2016.

Further, we would like to inform you that, the Board of Directors of the company have approved the appointment of Dr. B. S. Ramesh and Dr. Amit Varma as Additional Directors of the Company effective from 10th November 2016.

The Meeting of the Board concluded at 4.00 P.M.

Request you to take this intimation on record.

For HealthCare Global Enterprises Limited


Sunu Manuel
Company Secretary and Compliance Officer

Encl: as above

HealthCare Global Enterprises Ltd.

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027. | PAN No. AAACC8412H.
91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : U15200KA1998PLC023489